TSTheodore A. Schuman

Theodore A. Schuman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Theodore A. Schuman has a total of 191 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Regional Nasal Drug Deposition in Pediatric vs. Adult Models: In vitro Insights into User Technique and Breathing Patterns Sensitivity

    by Mohammad Hejazi, Xiomara Owen, David J. Edwards, Michael Hindle, Worth Longest, Theodore Schuman, Ross Walenga, Steven Chopski, Anubhav Kaviratna, Bryan Newman, et al.

    Purpose: Although in vitro studies recommended for establishing bioequivalence of locally acting nasal suspension products provide useful information regarding product performance, currently they are not designed to fully account for variability introduced by patient-specific factors such as administration technique and breathing patterns. This limitation, combined with ethical and practical challenges in conducting pediatric clinical trials, creates a knowledge gap in understanding age-related differences in nasal drug delivery. Methods: Anatomically realistic in vitro nasal models representing an average child and adult, in terms of total drug delivery to the sites of intended action posterior to nasal valve, were used to investigate the sensitivity of regional nasal drug deposition to variations in administration parameters and breathing conditions. Three breathing conditions were evaluated: breath hold, gentle sniffing, and vigorous sniffing. Administration parameters were varied using a Box-Behnken experimental design. Results: Results showed that for commercially available nasal sprays, breathing patterns did not significantly affect drug delivery in the adult model, but extreme conditions (no breathing vs. vigorous sniffing) caused significant differences in anterior deposition in the child model. Differences between gentle sniffing and the other conditions were not statistically significant. The sensitivity analysis revealed that in vitro drug deposition patterns differ between child and adult nasal cavities under identical user parameter variations, and variable importance differed across nasal cavity regions. Conclusions: This study demonstrates the potential for targeted drug delivery by enabling the identification of the optimal administration parameters to achieve desired outcomes, such as enhanced drug deposition in specific nasal regions.


  • Open Access

    Sinonasal Intervention Reduces the Need for Pressure Equalization Tube Placement in Atopic Adults

    by Lawrance Lee, Mihai A. Bentan, Elizabeth Mastoloni, Theodore A. Schuman

    Objectives: To determine the impact of management of upper airway atopic disease on middle ear and eustachian tube function in adults.Methods: The TriNetX Research Network was queried to construct cohorts of adult patients with atopic disorders of the upper airway (defined by ICD‐10 codes for asthma, allergic rhinitis, and chronic rhinosinusitis with nasal polyposis) with concurrent eustachian tube dysfunction (ETD) undergoing medical or surgical intervention for their atopic disease, including monoclonal antibody (mAb) therapy (e.g., dupilumab, mepolizumab, omalizumab), topical nasal steroid spray (fluticasone propionate), functional endoscopic sinus surgery (FESS), septoplasty with inferior turbinate submucosal resection (BITSMR), and allergy immunotherapy. The primary measured outcome was the difference in the rate of pressure equalization tube (PET) placement before and after each intervention.Results: FESS demonstrated an absolute risk reduction (ARR) of 10.0% (p < 0.05, 95% confidence interval [CI] 8.9%–11.1%), septoplasty/BITSMR 7.5% (p < 0.05, 95% CI 6.3%–8.7%), mAb 5.5% (p < 0.05, 95% CI 4.1%–6.8%), nasal steroid spray (fluticasone proprionate) 0.9% (p < 0.05, 95% CI 0.8%–1.0%), and allergy immunotherapy 2.4% (p < 0.05, 95% CI 1.5%–3.2%). Individually, the three mAb—dupilumab, mepolizumab, and omalizumab—exhibited ARR of 6.5% (p < 0.05%, 95% CI 4.8%–8.3%), 6.8% (p < 0.05, 95% CI 2.6%–11.0%), and 3.4% (p < 0.05, 95% CI 1.4%–5.4%), respectively, without significant differences in rates of PET placement among the three (p = 0.18).Conclusion: Management of upper airway atopic disorders via both medical and surgical intervention is associated with improvement in middle function as measured by the need for PET placement.Level of Evidence: 3.


  • Open Access

    Impact of elexacaftor/tezacaftor/ivacaftor CFTR modulator therapy on rates of endoscopic sinus surgery in cystic fibrosis

    by Graham Pingree, Mihai Bentan, Thomas Fitzpatrick, Theodore Schuman

    Background: Elexacaftor/tezacaftor/ivacaftor (ETI), a combination cystic fibrosis transmembrane receptor (CFTR) modulator, has demonstrated improved pulmonary outcomes in individuals with cystic fibrosis (CF). However, ETI's impact on functional endoscopic sinus surgery (FESS) remains unclear.Methods: The TriNetX Analytics Research Network, consisting of 120 million global de‐identified electronic medical records, was queried from 2012 to 2023 for subjects with CF who underwent sinus surgery.1 Patients on ETI prior to FESS (n = 6,056) were propensity score matched to control individuals with CF not on CFTR modulators (n = 37,906) and those on other FDA‐approved CFTR modulators (tezacaftor/ivacaftor, lumacaftor/ivacaftor, and ivacaftor) (n = 2437) based on relevant factors. The primary outcome was the absolute risk reduction (ARR) of undergoing FESS. Secondary outcomes included ARR of CF‐related pulmonary exacerbations and hospital admission from 0 to 6, 6 to 12, and 12 to 24 months following FESS.Results: ETI use demonstrated a significant ARR for FESS when compared to CF patients not on CFTR modulators (2.12%; 95% confidence interval [CI] 1.5–2.75; p‐value < 0.0001) and those on other CFTR modulators (4.7%; 95% CI 3.54–5.85; p‐value < 0.0001). No significant differences occurred in secondary outcomes between ETI and non‐CFTR modulator groups, except for reduced CF‐related pulmonary exacerbations from 0 to 6 months post‐FESS. Additionally, a significant reduction in pulmonary exacerbations was observed at all time points and hospital admissions within 6 months following FESS compared to those using other CFTR modulators.Conclusions: In a large dataset, CF patients on ETI demonstrated significantly reduced risk of FESS, pulmonary exacerbations, and hospital admission compared to patients not on CFTR modulators or those on other CFTR modulators, suggesting improved sinonasal disease and overall health status in CF.


  • Treatment of unilateral olfactory neuroblastoma: Appropriate extent of surgical resection and potential for olfactory preservation

    by Harish Dharmarajan, Garret Choby, Ralph Abi Hachem, Edward C. Kuan, Corinna G. Levine, Olabisi Sanusi, Theodore Schuman, Dennis Tang, Michael Yim, Mathew Geltzeiler

    Historically, comprehensive surgical resection for olfactory neuroblastoma has included the bilateral olfactory epithelium, cribriform plate, overlying dura, olfactory bulbs and tracts. This results in postoperative anosmia that may significantly impact a patient's quality of life without definitive added benefit in survival. The prevalence of occult intracranial disease is low, especially for Hyams grade I and II tumors. A unilateral approach sparing the contralateral cribriform plate and olfactory system can be considered for select cases of early stage, low‐grade tumors when the disease does not cross midline to involve the contralateral olfactory cleft or septal mucosa and when midline dural margins can be cleared with frozen pathology. Approximately half of patients who undergo unilateral resection may have residual olfaction even with adjuvant unilateral radiation. Early data suggest favorable disease‐free survival and overall survival for patients who underwent the unilateral approach; however, larger sample studies are needed to confirm comparability to bilateral resections regarding oncologic outcomes.


  • Impact of dual electronic and conventional cigarette use on diagnosis and surgery for chronic rhinosinusitis: A multicenter study

    by Graham Pingree, Jonathan DeShazo, Theodore Schuman

    Key pointsDual EC/CC users had a significantly greater risk of CRS or FESS when compared to solo users.Dual EC/CC users did not have a significantly greater risk of polyposis when compared to solo users.This effect likely relates to bacterial, immune cell, genetic, and mucociliary alterations.


  • Top Cited Papers
    Open Access

    International consensus statement on allergy and rhinology: Allergic rhinitis – 2023

    by Sarah K. Wise, Cecelia Damask, Lauren T. Roland, Charles Ebert, Joshua M. Levy, Sandra Lin, Amber Luong, Kenneth Rodriguez, Ahmad R. Sedaghat, Elina Toskala, et al.

    Background: In the 5 years that have passed since the publication of the 2018 International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (ICAR‐Allergic Rhinitis 2018), the literature has expanded substantially. The ICAR‐Allergic Rhinitis 2023 update presents 144 individual topics on allergic rhinitis (AR), expanded by over 40 topics from the 2018 document. Originally presented topics from 2018 have also been reviewed and updated. The executive summary highlights key evidence‐based findings and recommendation from the full document.Methods: ICAR‐Allergic Rhinitis 2023 employed established evidence‐based review with recommendation (EBRR) methodology to individually evaluate each topic. Stepwise iterative peer review and consensus was performed for each topic. The final document was then collated and includes the results of this work.Results: ICAR‐Allergic Rhinitis 2023 includes 10 major content areas and 144 individual topics related to AR. For a substantial proportion of topics included, an aggregate grade of evidence is presented, which is determined by collating the levels of evidence for each available study identified in the literature. For topics in which a diagnostic or therapeutic intervention is considered, a recommendation summary is presented, which considers the aggregate grade of evidence, benefit, harm, and cost.Conclusion: The ICAR‐Allergic Rhinitis 2023 update provides a comprehensive evaluation of AR and the currently available evidence. It is this evidence that contributes to our current knowledge base and recommendations for patient evaluation and treatment.


  • Glomangiopericitomas: uma série de casos com revisão da literatura

    by Aasif A. Kazi, Elizabeth M. McDougal, Jessica B. Howell, Theodore A. Schuman, Ryan S. Nord

  • Open Access

    Impact of the COVID‐19 pandemic on otolaryngology resident rhinology education

    by Akshay K. Murthy, Christian T. Fontan, Maria Filippa Trikantzopoulou, Thomas H. Fitzpatrick, Joshua M. Levy, Jeremiah A. Alt, Theodore A. Schuman


  • Open Access

    Glomangiopericytoma: a case series with review of literature

    by Aasif A. Kazi, Elizabeth M. McDougal, Jessica B. Howell, Theodore A. Schuman, Ryan S. Nord